The company reported that at the moment they do not need changes in the formula. But they are already evaluating a “specific modified version” in case the SARS-CoV-2 coronavirus mutates enough.
“To date there is no evidence that an adaptation of BioNTech’s current coronavirus vaccine against the identified variants is necessary,” the company said in a statement.
Nonetheless, BioNTech said in March that it began testing for a “modified, variant-specific version,” anticipating the need at some point to make adjustments to its current vaccine.
“This study aims to explore the regulatory path that BioNTech and Pfizer will have to follow if the SARS-CoV-2 virus were to change enough to require an updated vaccine, ” he said.
An evaluation is also underway on the impact of a possible third dose of the vaccine to extend immunity and protect against virus variants.
BioNTech founder and director Ugur Sahin said in April that the vaccine protects against the Indian variant of the virus.
The BioNTech / Pfizer vaccine was the first to be licensed in Western countries, and has been shipped to dozens of nations.
It is currently applied in more than 90 countries and its production is expected to reach 3,000 million doses by the end of this year.